RxDoctor Payments DataLook up a doctor →

Lisa Sanders

Family · Tupelo, MSNPI 1124161849

Payments from drug & device makers

$15,840in general payments, 2019–2025

Across 848 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$1K
  • Biogen$951
  • SK Life Science, Inc.$808
  • Novartis$759
  • AstraZeneca$691
  • plus $8K from 46 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$740%
  • Food & beverage$15,43197%
  • Education$1851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,840 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$80,063
Medicare patients
550
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine20$186,302
Aimovig AutoinjectorErenumab-Aooe182$137,181
Nurtec OdtRimegepant Sulfate90$128,042
Emgality PenGalcanezumab-Gnlm98$75,953
Trokendi XrTopiramate11$67,222
QuliptaAtogepant47$56,764
KeppraLevetiracetam20$38,223
Lacosamide170$26,776
Levetiracetam555$22,300
BriviactBrivaracetam13$19,559
EliquisApixaban11$18,490
LamictalLamotrigine11$16,661
UbrelvyUbrogepant14$15,230
VimpatLacosamide13$15,031
Ajovy AutoinjectorFremanezumab-Vfrm18$14,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$557$186,30220 claims
PfizerNurtec Odt, Eliquis$1,145$146,533101 claims
AbbVieQulipta, Ubrelvy$3,187$71,99461 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$42$67,22211 claims
UCB, Inc.Briviact, Vimpat$512$34,59126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →